ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1620

Antibody to Malondialdehyde-Acetaldehyde Adducts (MAA) As a Potential Biomarker of Inflammation in Systemic Lupus Erythrematosus (SLE)

Andy Hollins1, Michael Duryee2, Michelene Hearth-Holmes3, Ted R. Mikuls1, Zhixin Zhang4, Kaihong Su5 and Geoffrey M. Thiele6, 1University of Nebraska Medical Center, Omaha, NE, 2Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 3Internal Medicine/Rheumatology Division, University of Nebraska Medical Center, Omaha, NE, 4Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, 5Eppley Cancer Institute, University of Nebraska Medical Center, Omaha, NE, 6Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Antibodies, Biomarkers, inflammation and patient, SLE

  • Tweet
  • Email
  • Print
Session Information

Session Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: Autoimmune Disease Transition, Disease Subsets and Prediction of Flares, Cytokines and Autoantibodies

Session Type: Abstract Submissions (ACR)

Background/Purpose

 Studies have shown that malondialdehyde-acetaldehyde (MAA) is formed as a result of lipid peroxidation of cellular membranes and is capable of binding or adducting to various macromolecules. MAA-adducted macromolecules are cytotoxic, proinflammatory and result in a robust specific adaptive immune response to the MAA structure. Previous studies have shown serum anti-MAA antibodies present in inflammatory diseases including; atherosclerosis, aortic aneurysm, alcoholic liver disease, and recently rheumatoid arthritis.  The purpose of this study was to examine the potential utility of anti-MAA antibody isotypes as biomarkers in systemic lupus erythematosus (SLE). We also explored whether anti-MAA antibody isotypes were associated with two novel biomarkers that we have recently demonstrated to be increased in SLE, neutrophil extracellular traps (NETs) and NOD27/NLRC5.

Methods

 Eighty-eight SLE patients, all satisfying ACR classification criteria, and 92 controls were examined. Serum antibody levels were measured by enzyme-linked immunosorbent assay (ELISA) for levels of IgG, IgA, and IgM specific to the MAA epitope.  Spearman correlation coefficients were used to examine associations of MAA isotypes with NETs and NOD27/NLRC5. 

Results

MAA IgG concentration was significantly higher (p=0.004) in SLE patients (M=488.7 mg/L) compared to controls (M=331.7 mg/L) Figure 1. There was a strong trend (p=0.064) observed in MAA IgM concentrations between SLE samples (M=769.7 mg/L) and controls (M=586.7 mg/L). There was no difference observed between control and SLE groups for MAA IgA concentrations. Levels of MAA IgG demonstrated modest but statistically significant correlations with levels of NOD27/NLRC5 (r=.256, p=0.0508) and NB4 NET (r=.213, p=0.048) within the SLE group.

Conclusion

These data show that patients with SLE have significantly higher levels of MAA IgG and IgM compared to controls. In addition, MAA IgG concentrations were positively correlated with circulating levels of NB4 NETs and NOD27, consistent with the increased inflammatory burden that characterizes SLE. MAA has been shown to contribute to protein modifications eliciting strong immune responses and recruitment of proinflammatory cytokines. Whether MAA adduct formation and resulting immune responses mediate tolerance loss in SLE, as has been shown in other conditions, or other complications of SLE such as premature atherosclerosis warrants further investigation. 

Figure 1.  Serum samples were assayed by ELISA for the presence of IgG anti-MAA antibodies. 

 


Disclosure:

A. Hollins,
None;

M. Duryee,
None;

M. Hearth-Holmes,
None;

T. R. Mikuls,
None;

Z. Zhang,
None;

K. Su,
None;

G. M. Thiele,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/antibody-to-malondialdehyde-acetaldehyde-adducts-maa-as-a-potential-biomarker-of-inflammation-in-systemic-lupus-erythrematosus-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies